Jack Allen Stock Analyst Profile - Baird Research Coverage - Stocknear

Jack Allen

Stock Analyst at Baird

(3.7)
# 2470
Out of 5,506 analysts
52
Total ratings
Success rate
Average return
Main Sectors:
Top Industries:

19 Stocks

Name Action PT Current % Upside Ratings Updated
TSHA Taysha Gene Therapie...
Maintains: Outperform
7 12
4.76 152.1% 5 Oct 2, 2025
VOR Vor Biopharma
Maintains: Neutral
5 20
37.46 -46.61% 4 Jun 27, 2025
FATE Fate Therapeutics
Maintains: Neutral
5 4
1.21 230.58% 2 May 14, 2025
ALLO Allogene Therapeutic...
Maintains: Outperform
12 9
1.33 576.69% 3 May 14, 2025
CARM CARISMA Therapeutics
Downgrades: Neutral
10 1
n/a n/a 3 Dec 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
80 40
15.02 166.31% 2 Nov 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
77 106
85.07 24.6% 5 Nov 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
24 18
19.96 -9.82% 2 Oct 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
180 180
18.1 894.48% 9 Sep 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
140 120
n/a n/a 3 Aug 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
8
2.04 292.16% 1 Jun 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
46 52
67.74 -23.24% 2 May 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
84
34.21 145.54% 1 Oct 31, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
200 25
n/a n/a 3 Sep 26, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
21 6
n/a n/a 2 Aug 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
5
1.67 199.4% 1 Nov 2, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
9
n/a n/a 1 Sep 13, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
n/a
n/a n/a 2 May 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
6 9
4.86 85.19% 1 Oct 7, 2021